171 related articles for article (PubMed ID: 35307979)
1. Respiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen.
Menard J; Seferian AM; Fleurence E; Barzic A; Binoche A; Labouret G; Coutier L; Vuillerot C; Bieleu BM; Gomez Garcia de la Banda M; Corvol H; Servais L; Taytard J
Pediatr Pulmonol; 2022 Jun; 57(6):1505-1512. PubMed ID: 35307979
[TBL] [Abstract][Full Text] [Related]
2. Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen.
Sansone VA; Pirola A; Albamonte E; Pane M; Lizio A; D'Amico A; Catteruccia M; Cutrera R; Bruno C; Pedemonte M; Messina S; Rao F; Roma E; Salmin F; Coratti G; Di Bari A; De Sanctis R; Pera CM; Sframeli M; Piastra M; Macagno F; Vita G; Bertini E; Mercuri E
J Pediatr; 2020 Apr; 219():223-228.e4. PubMed ID: 32035635
[TBL] [Abstract][Full Text] [Related]
3. Respiratory characteristics in children with spinal muscular atrophy type 1 receiving nusinersen.
Xiao L; Chiang J; Castro-Codesal M; Kolski H; Bedi P; Al Amrani F; Gonorazky HD; Amin R;
Pediatr Pulmonol; 2023 Jan; 58(1):161-170. PubMed ID: 36193036
[TBL] [Abstract][Full Text] [Related]
4. Respiratory and sleep outcomes in children with SMA treated with nusinersen - real world experience.
Gonski K; Chuang S; Teng A; Thambipillay G; Farrar MA; Menezes MP; Fitzgerald DA
Neuromuscul Disord; 2023 Jun; 33(6):531-538. PubMed ID: 37290230
[TBL] [Abstract][Full Text] [Related]
5. Nusinersen for spinal muscular atrophy type 1: Real-world respiratory experience.
Lavie M; Diamant N; Cahal M; Sadot E; Be'er M; Fattal-Valevski A; Sagi L; Domany KA; Amirav I
Pediatr Pulmonol; 2021 Jan; 56(1):291-298. PubMed ID: 33111497
[TBL] [Abstract][Full Text] [Related]
6. Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen.
Ergenekon AP; Yilmaz Yegit C; Cenk M; Gokdemir Y; Erdem Eralp E; Ozturk G; Unver O; Kenis Coskun O; Karadag Saygi E; Turkdogan D; Karadag B
Pediatr Int; 2022 Jan; 64(1):e15175. PubMed ID: 35522792
[TBL] [Abstract][Full Text] [Related]
7. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy.
Hepkaya E; Kılınç Sakallı AA; Ülkersoy İ; Başkan AK; Arslan H; Meral Ö; Dilek TD; Güler S; Saltık S; Çokuğraş H
Pediatr Int; 2022 Jan; 64(1):e15310. PubMed ID: 36310036
[TBL] [Abstract][Full Text] [Related]
8. Nusinersen improved respiratory function in spinal muscular atrophy type 2.
Tanaka R; Fukushima F; Motoyama K; Kobayashi C; Izumi I
Pediatr Int; 2021 Aug; 63(8):973-974. PubMed ID: 34245199
[No Abstract] [Full Text] [Related]
9. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy.
Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Schwersenz I; Walter MC; Baumann M; Baumgartner M; Deschauer M; Eisenkölbl A; Flotats-Bastardas M; Hahn A; Horber V; Husain RA; Illsinger S; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Stögmann E; Trollmann R; Vill K; Weiß C; Wiegand G; Ziegler A; Lochmüller H; Kirschner J;
Brain; 2023 Feb; 146(2):668-677. PubMed ID: 35857854
[TBL] [Abstract][Full Text] [Related]
10. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
[TBL] [Abstract][Full Text] [Related]
11. Children and young adults with spinal muscular atrophy treated with nusinersen.
Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J
Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321
[TBL] [Abstract][Full Text] [Related]
12. Sleep architecture and Nusinersen therapy in children with Spinal Muscular Atrophy type 1.
Verrillo E; Pavone M; Bruni O; Ferri R; Chiarini Testa MB; Cherchi C; D'Amico A; Cutrera R
Sleep Med; 2023 Oct; 110():106-110. PubMed ID: 37572575
[TBL] [Abstract][Full Text] [Related]
13. Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1-3.
Chacko A; Sly PD; Ware RS; Begum N; Deegan S; Thomas N; Gauld LM
Thorax; 2022 Jan; 77(1):40-46. PubMed ID: 33963091
[TBL] [Abstract][Full Text] [Related]
14. Changing respiratory expectations with the new disease trajectory of nusinersen treated spinal muscular atrophy [SMA] type 1.
Fitzgerald DA; Doumit M; Abel F
Paediatr Respir Rev; 2018 Sep; 28():11-17. PubMed ID: 30414815
[TBL] [Abstract][Full Text] [Related]
15. Nusinersen for SMA: expanded access programme.
Farrar MA; Teoh HL; Carey KA; Cairns A; Forbes R; Herbert K; Holland S; Jones KJ; Menezes MP; Morrison M; Munro K; Villano D; Webster R; Woodcock IR; Yiu EM; Sampaio H; Ryan MM
J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):937-942. PubMed ID: 29549190
[TBL] [Abstract][Full Text] [Related]
16. Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea.
Shin HJ; Na JH; Lee H; Lee YM
Yonsei Med J; 2023 Dec; 64(12):705-711. PubMed ID: 37992742
[TBL] [Abstract][Full Text] [Related]
17. Nutritional Therapy in Children With Spinal Muscular Atrophy in the Era of Nusinersen.
Yerushalmy-Feler A; Levy D; Sagi L; Fattal-Valevski A; Shiff YE; Brener A; Cohen S
J Pediatr Gastroenterol Nutr; 2021 Jun; 72(6):e154-e160. PubMed ID: 33492038
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland.
Tscherter A; Rüsch CT; Baumann D; Enzmann C; Hasselmann O; Jacquier D; Jung HH; Kruijshaar ME; Kuehni CE; Neuwirth C; Stettner GM; Klein A;
Neuromuscul Disord; 2022 May; 32(5):399-409. PubMed ID: 35337708
[TBL] [Abstract][Full Text] [Related]
19. Nonrespiratory complications of nusinersen-treated spinal muscular atrophy type 1 patients.
Lavie M; Rochman M; Sagi L; Yerushalmy Feler A; Ovadia D; Cahal M; Be'er M; Sadot E; Fattal-Valevski A; Amirav I
Pediatr Pulmonol; 2022 Mar; 57(3):686-694. PubMed ID: 34921596
[TBL] [Abstract][Full Text] [Related]
20. Evolution of bulbar function in spinal muscular atrophy type 1 treated with nusinersen.
Weststrate H; Stimpson G; Thomas L; Scoto M; Johnson E; Stewart A; Muntoni F; Baranello G; Conway E;
Dev Med Child Neurol; 2022 Jul; 64(7):907-914. PubMed ID: 35103306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
